Raising the bar for using surrogate endpoints in drug regulation and health technology assessment

Authors:

Abstract
Surrogate endpoints provide no guarantee of clinical benefit, and Dalia Dawoud and colleagues argue they should be used only as a last resort in drug trials

This publication has 55 references indexed in Scilit: